Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-25-256667
Filing Date
2025-10-29
Accepted
2025-10-29 17:16:14
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4900
  Complete submission text file 0001193125-25-256667.txt   6517
Mailing Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH
Business Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH 44 020 7788 7414
Virax Biolabs Group Ltd (Subject) CIK: 0001885827 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94426 | Film No.: 251430979
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 20 NORTH AUDLEY STREET LONDON X0 W1K 6LX
Business Address
Foster James Alexander Cunliffe (Filed by) CIK: 0001988784 (see all company filings)

Type: SCHEDULE 13G/A